IP Library Granted Patent US 7,879,813
Granted Patent B2
US 7,879,813 · App. 12/338,252 · Granted Feb 1, 2011

Interfering RNA delivery system and uses thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,879,813
App. No.
12/338,252
Granted
Feb 1, 2011
Kind
B2
Abstract

The invention provides a delivery system comprising a cell penetrating peptide, a polyarginine peptide, and an interfering RNA molecule. The system can be used for delivering interfering RNA molecules into a cell in vivo or in vitro. Therapeutic uses for the delivery system are also provided.

Claims (13)

1. A method of treating an ocular disorder in a patient, comprising administering to the patient the interfering RNA delivery system comprising an interfering RNA molecule linked to a cell penetrating peptide (CPP)-Arg peptide, wherein the interfering RNA molecule can attenuate expression of a gene associated with the ocular disorder, and wherein the CPP-Arg peptide comprises the sequence as set forth in SEQ ID NO: 12.

2. The method of claim 1 , wherein the ocular disorder is associated with ocular angiogenesis, dry eye, ocular inflammatory conditions, ocular hypertension, or glaucoma.

3. The method of claim 1 , wherein the system is administered by intraocular injection, ocular topical application, subconjunctival injection, intravitreal injection, anterior or posterior juxtascleral injection, intravenous injection, oral administration, intramuscular injection, intraperitoneal injection, transdermal application, intranasal application, or transmucosal application.

4. A method of delivering an interfering RNA molecule into a cell, comprising:

(a) attaching an interfering RNA molecule to a CPP-Arg peptide, thereby forming an interfering RNA delivery system, wherein the CPP-Arg peptide comprises the sequence as set forth in SEQ ID NO: 12; and

(b) administering the interfering RNA delivery system to the cell under conditions suitable for the system to enter the cell.

5. The method of claim 4 , wherein release of the system from the endosome inside the cell is enhanced in the presence of an HA2 peptide.

6. The method of claim 5 , wherein the HA2 peptide is introduced into the cell by administration of a CPP-HA2 peptide.

7. The method of claim 4 , wherein the CPP-Arg peptide further comprises the HA2 peptide.

8. The method of claim 4 , wherein the interfering RNA molecule is linked to the CPP-Arg peptide via a covalent bond.

9. The method of claim 4 , wherein the interfering RNA molecule is a siRNA, miRNA, or shRNA.

10. The method of claim 4 , wherein the CPP has an amino acid sequence in the forward or reverse direction.

11. The method of claim 10 , wherein the CPP comprises at least one D-amino acid.

Assignments (4)
CHANGE OF NAME Recorded Aug 12, 2024
From: ARROWHEAD RESEARCH CORPORATION
To: ARROWHEAD PHARMACEUTICALS, INC.
Reel/Frame 068552/0799 →
SECURITY INTEREST Recorded Aug 7, 2024
From: ARROWHEAD PHARMACEUTICALS, INC.
To: SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT
Reel/Frame 068510/0363 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 13, 2015
From: ALCON RESEARCH, LTD.
To: ARROWHEAD RESEARCH CORPORATION
Reel/Frame 035653/0635 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 18, 2008
From: CHATTERTON, JON E.
To: ALCON RESEARCH, LTD.
Reel/Frame 022002/0730 →